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Available online 11 November 2016Background: The LifeLines Cohort Study is a large three-generation prospective study and Biobank. Recruitment
and data collection started in 2006 and follow-up is planned for 30 years. The central aim of LifeLines is to under-
stand healthy ageing in the 21st century. Here, the study design, methods, baseline and major cardiovascular
phenotypes of the LifeLines Cohort Study are presented.
Methods and results:Baseline cardiovascular phenotypeswere deﬁned in 9700 juvenile (8–18 years) and 152,180
adult (≥18 years) participants. Cardiovascular disease (CVD) was deﬁned using ICD-10 criteria. At least one car-
diovascular risk factor was present in 73% of the adult participants. The prevalence, adjusted for the Dutch pop-
ulation, was determined for risk factors (hypertension (33%), hypercholesterolemia (19%), diabetes (4%),
overweight (56%), and current smoking (19%)) and CVD (myocardial infarction (1.8%), heart failure (1.0%),
and atrial ﬁbrillation (1.3%)). Overall CVD prevalence increased with age from 9% in participants b 65 years to
28% in participants ≥ 65 years. Of the participantswith hypertension, hypercholesterolemia and diabetes, respec-
tively 75%, 96% and 41% did not receive preventive pharmacotherapy.
Conclusions: The contemporary LifeLines Cohort Study provides researchers with unique and novel opportunities
to study environmental, phenotypic, and genetic risk factors for CVD and is expected to improve our knowledge
on healthy ageing. In this contemporaryWestern cohortwe identiﬁed a remarkable high percentage of untreated
CVD risk factors suggesting that not all opportunities to reduce the CVD burden are utilised.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Epidemiology1. Introduction
Healthy ageing is one of the topics in ‘Horizon 2020— Personalising
Health and Care’; “the biggest EuropeanUnion Research and Innovation
programme” aimed to ensure Europe's global competitiveness [1]. The
goal of Horizon 2020 is to gain insight in factors and interactions com-
prising the development andmaintenance of good health and the pres-
ence and progression of common diseases and disabilities. Throughout
life, underlying genetic make-up and modiﬁable lifestyle factors such
as behavior, environment and nutrition interact in this process in vary-
ing degrees.
Despite recent progress with novel therapies, a major threat to
healthy ageing is cardiovascular disease (CVD) [2–5]. CVD affects thee reliability and freedom from
ion.
rsityMedical Center Groningen,
gen, The Netherlands.
arst).
rtman,M.D., contributed equal-
land Ltd. This is an open access articlmajority of adults over 60 years of age. In 2012, it was estimated to be
the cause of 17.3 million deaths worldwide [6]. In the EU, the main
cause of death is CVD and accounts for 1.9 million deaths every year
[2]. CVD also causes substantial morbidity with an annual hospital dis-
charge rate of 2400 per 100,000 population.
Epidemiologic studies in the past, including the Framingham Heart
study initiated in 1948, have contributed enormously to our under-
standing of CVD and its risk factors [7]. However, after identiﬁcation of
risk factors with large effect size the power of many previous studies
to test for smaller effect sizes or gene-environment interactions is limit-
ed. In addition, these cohorts date back to the 90s, and advances in treat-
ment as well as changes in behavior and lifestyle have occurred. To
further our knowledge of genes, environment and their interaction de-
termining CVD and healthy ageing contemporary population-based
biobanks are essential. The LifeLines Cohort Study, established in 2006,
is a contemporary observational population-based study designed to
enhance our understanding of healthy ageing in the 21st century [8].
Baseline characteristics of 167,729 inhabitants of the Northern part of
the Netherlands have been collected. The ﬁrst follow-up visit at ﬁve
years is ongoing and the second 10-year follow-up visit is scheduled.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ity that is open for all researchers, information on application and data
access procedures is summarized on www.lifelines.net. Here we sum-
marize the baseline characteristics, and provide detailed information
on the prevalence of CVD, cardiovascular risk factors and treatment
thereof. In addition, we aim to inform and encourage researchers to
consider LifeLines Cohort Study for their future research projects.
2. Methods
2.1. Overall design of the LifeLines Cohort Study
The overall design and rationale of the LifeLines Cohort Study have been described in
detail elsewhere [8,9]. In brief, individuals living in the recruitment area aged between 25
and 50,were invited through their general practitioners (GP). Individualswere not invited
when the participating GP considered the patient not eligible by reason of severe psychi-
atric of physical illness; limited life expectancy or insufﬁcient knowledge of the Dutch lan-
guage. In addition, inhabitants of the Northern provinces, who were not invited by their
GP and not meeting above-mentioned reasons, could register themselves via the LifeLines
website. After signing informed consent, participants received a baseline questionnaire
and an invitation to a health assessment at one of the LifeLines research sites. During
these visits, participants were asked whether their family members would also be willing
to participate. Overall, 49% of the participants (n=81.652)were invited through their GP,
38% (n=64.489) via participating family members and 13% (n= 21.588) self-registered
via the LifeLineswebsite. In total, 167,729 participantswere included from the end of 2006
until December 2013 and data of 167,016 participants were suitable for further analysis.
The 5-year follow-up visit physical examination at the LifeLines research site is currently
ongoing and the 10-year follow-up visit is planned. In addition, participants receive a
follow-up questionnaire every 18 months. By using a third-party pseudo-anonymization
system, records of GPs, pharmacies and other health and national registries are being
linked with the LifeLines database. Data was analyzed for different pre-speciﬁed age cate-
gories, namely juvenile (aged 8–18 years), young and middle-age adults (≥18 and b65)
and older aged (65+) participants. Data collection within LifeLines is dynamic, add-on
studies are continuously implemented in LifeLines.
2.2. Cardiovascular data collection
2.2.1. Questionnaires
Self-reported questionnaires were used to obtain information on demographics, fam-
ily composition, work and education, general health, lifestyle, environmental and psycho-
social factors. Lifestyle and environment questions included information on physical
activity (SQUASH questionnaire), nutrition (FFQ questionnaire), smoking, physical envi-
ronment and daytime activities. Psychosocial factors included questions on perceived
quality of life, health perception, personality, stress and social support [8]. Drug use was
collected in the questionnaire and categorized using the general Anatomical Therapeutic
Chemical Classiﬁcation System (ATC) codes. We recently reported a global overview of
the deﬁnitions of CVD and non-CVD in a subpopulation of LifeLines [10].
2.2.2. Physical examination
At baseline, participants were invited to visit one of twelve LifeLines Research sites to
undergo a physical examination and a series of tests. During the baseline visits height
without shoes was measured with the SECA 222 stadiometer and rounded to the nearest
0.5 cm.Weight without shoes and heavy clothing wasmeasured with SECA 761 scale and
rounded to the nearest 0.1 kg.Waist and hip circumference wasmeasuredwith SECA 200
measuring tape and rounded to the nearest 0.5 cm. Blood pressure was measured ten
times during 10minwith Dynamap, PRO 100V2. The blood pressure registeredwas calcu-
lated by averaging the ﬁnal three readings inmmHg. Heart rate was collected and report-
ed in beats per minute. Pulmonary functionwasmeasured oncewithWelch Allyn version
1.6.0.489 and a 12-lead electrocardiogram (ECG) was recorded with aWelch Allyn DT100
machine. Skin autoﬂuorescence was measured at the lower arm with advanced glycation
end products (AGE)-reader (AGEreader, DiagnOptics Technologies B.V., The Netherlands).
2.2.3. Biomaterial collection and biobanking
At the research sites, blood and 24-hour urine was collected from participants and
transported to the central LifeLines laboratory inGroningen. For performing clinical chem-
istry analyses on fresh blood and 24-hour urine samples, part of the samples was directly
transferred to the central laboratory of the University Medical Center Groningen (UMCG).
From the remaining blood samples, part has been used for DNA isolation (from whole
blood of all LifeLines participants aged 8 years and older) and was stored at−80 °C. Nor-
malized DNA was stored at 4 °C. The remaining blood and 24-hour urine samples were
stored at −80 °C and are available for future research questions. In addition to blood
and urine, faeces of more than 50.000 participants have been collected and a hair scalp
will be collected from all participants during the ﬁrst follow-up visit.
2.2.4. Genotyping data
Currently, genome-wide genotyping data is available of 13,436 participants. These
data have been generated using the Illumina CytoSNP-12v2 array, after which they were
called in GenomeStudio (Illumina, Inc., San Diego, California, USA). Quality control was
performed with PLINK, after which 268,407 SNPs and 13,436 samples remained.2.2.5. Ultra-low-dose CT imaging
A substudy (IMALIFE) is currently being established on ultra-low-dose CT scanning of
the thorax. To determine normal values of lung density, bronchial wall thickness and cor-
onary calcium by age and gender, 12,000 randomly assigned participants will undergo CT
scanning after signing additional informed consent.
For a complete overview of the available LifeLines data visit the LifeLines website at
www.lifelines.net and the online data catalogue at https://catalogue.lifelines.nl/.
3. Deﬁnitions
3.1. Cardiovascular risk factors
Self-reported CVD risk factors were deﬁned as present when they
were afﬁrmatively answered in the questionnaire and as being absent
when answered negatively or missing. In addition, physical examina-
tion data at baseline visit was used to deﬁne and validate CVD risk fac-
tors speciﬁed by the following criteria (Supplementary Figs. 1–7 show
the operationalizationmethods for deﬁning cardiovascular risk factors).
Overweight was deﬁned as a body mass index (BMI) above 25.0 kg/m2.
In juvenile participants, overweight was deﬁned according to World
Health Organization (WHO) child growth standards with BMI-for-age
[11].
Smoking included past and current smokers. Active smoking in
adults was deﬁned as having smoked the past month or now. Former
adult smokers were deﬁned as answering the question ‘have you
stopped smoking’ conﬁrmatively. Data on smoking was available in ju-
veniles aged 13 years and over. Active smoking in juveniles was deﬁned
as answering the question “does your child still smoke” conﬁrmatively.
Former smoking was deﬁned as answering the question “did your child
smoke daily” conﬁrmatively and followed by the question “does your
child still smoke” answered negatively. The question “Being active for
at least half an hour a day”, was the deﬁnition for active lifestyle in
adults, which was obtained from the questionnaire as well. In juveniles
aged 8 years and over active lifestyle was deﬁned as doing sports or
playing outside for more than 7 h aweek. Cancer and blood clotting dis-
order were considered to be present when they were afﬁrmatively an-
swered in the questionnaire. The Systematic Coronary Risk Evaluation
Project (SCORE) risk was determined in adult participants with avail-
able cholesterol and blood pressure measurements [12].
3.2. Cardiovascular disease
By questionnaire, participants were asked to report presence of CVD
and related symptoms. Operationalization methods were generated
for deﬁning (silent) myocardial infarction (MI), heart failure and atrial
ﬁbrillation (Supplementary Figs. 8–11). With the help of these
operationalization methods self-reported CVD or related symptoms
were validated with biomarkers or cardiovascular medication. The
total number of CVD per participant was determined. The deﬁnition
for CVDwas based on the ICD-10 and included all CVD that could be ver-
iﬁed in the LifeLines database; MI, heart failure, atrial ﬁbrillation, heart
valve disorders, arrhythmia, aneurysm, stroke, thrombosis, atheroscle-
rosis, narrowing carotid arteries and a history of coronary artery bypass
grafting (CABG) [13].
3.3. Statistical analysis
Normally distributed continuous variables were presented with
mean and standard deviation. Continuous variables not normally dis-
tributed were presented as medians with interquartile ranges (IQR)
and categorical variables as percentages. The Chi-square test was used
to compare frequencies of events in the middle (aged ≥18 and b65)
and older (aged 65+) aged group. Differences in continuous variables,
not normally distributed, were ascertained by two-sample Wilcoxon
rank-sum (Mann–Whitney) test. Age and sex standardized estimates
were calculated with standardized rates for the variables, deﬁned as
theweighted average of stratum-speciﬁc rates. These rates are averaged
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distribution of age and sex of adults 18 years and over (13,060,511) in
the Netherlands in 2010. This is implemented with the dstdize com-
mand in STATA, an algebraically equivalent of the Cochran's formula
[14]. Logistic regression was performed to assess the correlation be-
tween cardiovascular risk factors and CVD, presented with odds ratios.
Adjustments for family relations were performed with the cluster op-
tion. Analyses were performed with STATA/IC version 13.0 (StataCorp
LP, College Station, Texas, USA).
3.4. Ethics policy
3.4.1. Declaration of Helsinki
The LifeLines Cohort Study state that the study complies with the
Declaration of Helsinki. The local ethics committee approved the re-
search protocol and informed consent was signed by every participant.
4. Results
The LifeLines Cohort Study population included 68,850 male and
83,330 female adults and 7231 male and 7605 female juveniles. In
total 60,401 participants were part of 42,351 families, including ﬁrst-,
second- and third-degree relatives, generating 112,050 family clusters.
The age and gender distribution of LifeLines participants differed sub-
stantially from the general population distribution in The Netherlands
(Fig. 1 and Table 1).
4.1. Baseline characteristics and cardiovascular risk factors
Physical examinationwas available on all participants. Lowerweight
was seen in the older aged group compared to themiddle age category;
in women the mean weight was 74 ± 14 (old age category) and 74 ±
12 kg (middle age category, p= 0.001) respectively and in men 88 ±
14 and 85 ± 11 kg (p b 0.001) respectively. The mean height of
women in the middle age category was higher compared to the older
age category (170 ± 7 cm versus 164 ± 6 cm, p b 0.001). The height
of men was lower in the older aged group: 183 ± 7 cm in the middle
age category compared to 177 ± cm in the older aged group
(p b 0.001). In total 61.9% (n = 35.878) of men were overweighed in
the middle age category compared to 48.5% (n = 40.450) of women
(Fig. 2). In the older age group, these proportions were higher: 73.5%
(n = 3774, p b 0.001) of men and 69.4% (n = 3967, p b 0.001) of
women. In contrast to the lower heart rate (72 ± 11 bpm in the
young and middle-age adults versus 68 ± 14 bpm in the older aged,
p b 0.001), systolic blood pressure was higher in older age categories
(124 ± 15 over 74 ± 9 mm Hg in the young and middle-age adults
vs. 137 ± 24 over 74 ± 12 mm Hg in the older aged, p b 0.001).Fig. 1. Population distribution in the Netherlands in 2010 and popAdditional biomarkers and cardiovascular drugusewere available (Sup-
plementary Table 1 and Table 2).
The prevalence of cardiovascular risk factors is presented in Table 1.
In 110,502 (72.6%) participants, at least one classical cardiovascular risk
factors (hypertension, hypercholesterolemia, diabetes mellitus, kidney
disease, overweight or current smoking) was present. As expected, the
burden of cardiovascular risk factors (SCORE) increased with age (Fig.
3A).
Cardiovascular drug use increased with age. Amongst the most pre-
scribed cardiovascular drugs were agents acting on the renin-
angiotensin system, lipid drugs and beta-blockers. Overall, 12.3% (n=
17.341) of the participants in the young and middle-age adults used
one or more cardiovascular drug compared to 54.8% (n = 5945,
p b 0.001) of the participants in the older aged group. However, of the
participants with hypertension 75.2% had no antihypertensive drugs,
for hypercholesterolemia 95.9% had no lipid lowering drugs, for diabe-
tes 41.2% had no anti-diabetic drugs.
The recent SPRINT trial proclaimed lower rates of cardiovascular
events in persons with strict blood pressure control (b120 mmHg)
[15]. In a recent publication investigating eligibility of SPRINT criteria
in U.S.A. adults, more than half of the adults with hypertension were
not treated [16]. In this cohort, of the participants with systolic blood
pressure higher than 130 mmHg (n = 54.026, 35.5%) 79.9% (n =
43.153) had no antihypertensive drugs. Of participants having a
SCORE predicting a ≥5% 10-year risk of fatal CVD, 53.2% were not
using any cardiovascular preventive drugs.
4.2. Cardiovascular disease
Symptoms possibly related to CVD were common. Chest pain and
dyspnea on exertion were reported by approximately 25% of all adult
participants. CVD and suggestive symptoms along are presented in
Table 2. CVD was present in 16,872 (11%) of adult participants and in-
creased with age from 9% in the middle age category to 28% in the
older age category. Fig. 3B shows total CVD burden in the LifeLines Co-
hort Study population. Prevalence of CVD increases substantially from
the age of 50 (p b 0.001). Interestingly, we observed that not only the
number of individuals with CVD increases, but the amount of reported
CVDmanifestations increases as well. Table 3 shows multivariate logis-
tic regression of CVD risk factors with corresponding odds ratios for
CVD. After adjustment for family clusters odds ratios were analogous.
5. Discussion
Here we describe the baseline cardiovascular characteristics of the
contemporary three-generations LifeLines Cohort Study with 167,016
participants. The risk factor burden of the LifeLines Cohort Study isulation distribution in the LifeLines Cohort Study population.
Table 1
Demographics and cardiovascular risk factors in the LifeLines Cohort Study.
Characteristics Juvenile 8–18 Y N Adults 18–65 Y N Adults 65+ Y N Crude estimate Standardized estimate
Age (years, mean ± SD) 9.11 ± 4.7 14,836 43 ± 11 141,327 71 ± 5 10,853 – –
Female 51.3% 7605 59.0% 83,330 52.7% 5720 – –
Ethnicity
White/East and West European – – 97.9% 109,574 99.0% 7484 – –
Mediterranean or Arabic – – 0.4% 406 0.1% b10 – –
Black – – 0.2% 189 b0.1% b10 – –
Asian – – 0.5% 570 0.2% 17 – –
Other – – 1.0% 1136 0.6% 47 – –
Cardiovascular risk factors
Self-reported hypertension – – 19.9% 28,059 36.8% 3993 21.1% 22.2%
Hypertension 0.4% 57 22.5% 31,748 69.0% 7487 25.8% 32.6%
Self-reported hypercholesterolemia – – 11.5% 16,234 29.2% 3168 12.8% 14.7%
Hypercholesterolemia 0.2% 35 12.8% 18,102 43.8% 4753 15.0% 19.1%
Self-reported diabetes mellitus – – 2.0% 2819 9.8% 1063 2.6% 3.5%
Diabetes mellitus 0.2% 31 2.6% 3646 11.7% 1270 3.2% 4.4%
Self-reported kidney disease – – 0.5% 655 1.0% 103 0.5% 0.6%
Kidney disease 0.3% 41 1.4% 1910 11.8% 1281 2.1% 4.6%
Overweight 13.0% 1933 54.0% 76,282 71.2% 7730 55.2% 56.2%
Active smoker 1.2% 184 21.5% 30,412 8.2% 893 20.6% 19.0%
Former smoker 0.4% 65 32.5% 45,953 52.4% 5687 33.9% 35.3%
Active lifestyle (30 min/day) 42.4% 6292 21.4% 30,257 23.7% 2567 21.6% 21.1%
Family health — CVD – – 8.9% 12,510 10.0% 1083 8.9% 8.8%
Cancer – – 3.8% 5331 15.8% 1709 4.6% 6.2%
COPD – – 9.9% 14,037 23.4% 2540 10.9% 12.6%
Rheumatoid arthritis – – 1.2% 1658 1.8% 199 1.2% 1.2%
Thyroid disease 0.2% 30 2.2% 3074 4.9% 536 2.4% 2.6%
Blood clotting disorder – – 0.6% 852 0.7% 77 0.6% 0.6%
Abbreviations: CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease.
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adjusting for population distribution. Over 70% of the participants had
at least one cardiovascular risk factor (hypertension, hypercholesterol-
emia, diabetesmellitus, kidney disease, overweight or current smoking)
and in a substantial proportion (11%) a manifestation of CVD was pres-
ent. Primary prevention of cardiovascular risk factors, evenwhen SCORE
predicted a 5% ormore risk, was remarkably low. The burden of risk fac-
tors and CVD present in the LifeLines Cohort Study provides consider-
able power to study events and risk factors related to CVD. It is
therefore a valuable tool for researchers to further study the role of
CVD and its risk factors in relation to healthy ageing.
The LifeLines study population differs from the general population
by its design to that effect that the proportion of adults aged 25–
50years are overrepresented [17]. Reported prevalences of CVD risk fac-
tors from the Dutch National Registry (Statistics Netherlands) based on
national health survey in around 15,000 persons, are frequently lowerFig. 2. Body mass index distribution for males and females in the middle and ocompared to the LifeLines Cohort Study [17]. This may be due to differ-
ent methods used for identifying and deﬁning disease. For example, ac-
cording to the Statistics Netherlands for 2013 and 2014 prevalence of
hypertension and overweight was around 11% lower [17]. Smoking
was estimated 4% higher than in the LifeLines Cohort Study,with a prev-
alence of 24.9% compared to 20.6%. In contrast, the WHO reported gen-
erally higher prevalences with hypercholesterolemia, diabetes and
overweight estimated 5% higher than in the LifeLines Study [18].
Discrepancies exist regarding physical activity. According to the
WHO in 2010 17.9% of adults from the Netherlands were insufﬁciently
active [18] and the StatisticsNetherlands reported 63% of thepopulation
attained sufﬁcient physical activity. These differences might be due to
the use of different deﬁnitions and measurements of physical activity.
The reported family history of CVD was four times higher in the Rotter-
dam study compared to the LifeLines, suggesting regional differences,
the use of different deﬁnitions, or underreporting in the LifeLines Cohortlder age category in the LifeLines Cohort Study, BMI = body mass index.
Fig. 3.Mean SCORE and CVD per age category in the LifeLines Cohort Study. SCORE = Systematic Coronary Risk Evaluation Project; CVD = cardiovascular disease.
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were somewhat lower compared to the Statistics Netherlands inquiry
in 2014, in which 3.1% of the total population ever had a stroke and
3.3% had a MI compared to respectively 0.8% and 1.1% in the LifeLines
study population.
In the Netherlands in 2012 drug use of lipid lowering drugs was
10.7%, betablockers 9.8% and diabetes 4.6%, similar as reported by the
participants of the LifeLines Cohort Study [17]. Interestingly, taking
into account the risk factor burden in participants with a predicted
risk of ≥5% of which the majority does not use cardiovascularTable 2
Cardiovascular disease in the LifeLines Cohort Study.
Characteristics Adults
18–65 Y
N Adults
65+ Y
N Crude
estimate
Standardized
estimate
MI, heart failure and atrial ﬁbrillation
Self-reported MI 0.7% 985 6.2% 665 1.1% 2.0%
With drug use or
ECG abnormalities
0.6% 852 5.6% 608 1.0% 1.8%
Silent MI 0.1% 162 0.5% 58 0.1% 0.2%
Possible diagnosis
silent MI
0.4% 549 1.4% 152 0.5% 0.7%
Self-reported heart
failure
0.6% 776 3.2% 342 0.7% 1.2%
With drug use or
therapy otherwise
0.4% 495 2.8% 307 0.5% 1.0%
Cardiac implantable
electronic device
0.1% 139 0.8% 87 0.2% 0.3%
Transplant b0.1% 10 b0.1% 14 b0.1% b0.1%
Atrial ﬁbrillation 0.3% 408 3.9% 426 0.6% 1.3%
Other self-reported CVD
Balloon angioplasty
or bypass surgery
0.9% 1323 8.4% 898 1.5% 2.8%
Heart valve disorder 0.9% 1237 3.1% 332 1.0% 1.4%
Palpitations 6.7% 9462 14.6% 1579 7.3% 8.0%
Aortic aneurysm 0.2% 266 1.9% 202 0.3% 0.6%
Stroke 0.6% 842 3.1% 336 0.8% 1.2%
Thrombosis 1.1% 1,55 2.9% 316 1.2% 1.4%
Atherosclerosis 0.4% 491 2.0% 214 0.5% 0.8%
Narrowing carotid
arteries
0.2% 271 1.5% 124 0.3% 0.4%
Symptoms
Peripheral edema 14.4% 20,038 23.9% 2082 14.5% 13.9%
Chest pain 26.5% 36,972 28.1% 2446 25.9% 25.8%
Shortness of breath 22.9% 31,567 19.6% 1703 21.9% 20.8%
Dyspnea 10.3% 14,436 6.6% 572 9.9% 9.1%
Dyspnea on exertion 25.9% 36,087 27.7% 2403 25.3% 24.7%
Orthopnea 3.5% 4899 4.2% 360 3.5% 3.2%
Abbreviations: ECG, electrocardiogram; MI, myocardial infarction; CVD, cardiovascular
disease.preventative drugs, there is likely to be a considerable underutilisation
of primary prevention. The General Practitioner has been informed
about the risk proﬁle of the LifeLines participant as part of the protocol
and in linewith the recommendation of theMedical Ethical Committee.
Follow-up studies will be performed to study whether this knowledge
has increased the percentage of subjects in whom primary prevention
was initiated.
Strengths of the Lifelines Cohort Study include the open protocol and
hence a continuous possibility for researches to implement add-on
studies. The three-generation structure in combination with the avail-
able genome-wide genetic data enables unique opportunities for the
analysis of genetic traits. In LifeLines, over one-thirds of the participants
had ﬁrst-, second-, or third-degree relatives also taking part in the
study. The family design of the LifeLines Cohort Study has advantages
with respect to multiple-level information, separation of non-genetic
and genetic familial transmission and the investigation of (epi)genetic
inﬂuences. Another advantage when performing genetic research, is
the relatively homogeneous study population due to a low migration
rate in the northern part of the Netherlands (net migration rate of 0.80
per 1000 inhabitants in 2012) [17]. Less than 2% of the total included
population had an ethnicity other than white-, east- or west-European.
Diversity regarding CVD exists within ethnicity groups, and reportedTable 3
Multivariate logistic regression: risk factors and CVD.
Characteristics p-Value Odds ratio 95% CI
Female b0.001 1.08 1.04–1.12
Age per year b0.001 1.04 1.03–1.04
Overweight 0.003 1.06 1.02–1.10
Smoking b0.001 1.21 1.17–1.26
Active lifestyle
Active 0 out of 7 days Reference – –
Active 1 out of 7 days b0.001 0.82 0.74–0.90
Active 2 out of 7 days b0.001 0.80 0.73–0.88
Active 3 out of 7 days b0.001 0.80 0.73–0.88
Active 4 out of 7 days b0.001 0.78 0.72–0.86
Active 5 out of 7 days b0.001 0.84 0.77–0.92
Active 6 out of 7 days b0.001 0.84 0.77–0.92
Active 7 out of 7 days b0.001 0.86 0.79–0.93
Family CVD b0.001 1.30 1.24–1.38
Cancer b0.001 1.15 1.08–1.24
Thyroid disease b0.001 1.53 1.39–1.68
Kidney disease b0.001 1.23 1.11–1.36
Hypercholesterolemia b0.001 1.84 1.77–1.92
Hypertension b0.001 2.14 2.06–2.23
Diabetes 0.025 1.10 1.01–1.19
Abbreviations: CVD, cardiovascular disease; CI, conﬁdence interval.
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applicable to other ethnicities.
6. Conclusion
The LifeLines Cohort Study is a large population based cohort acces-
sible to national and international researchers [8]. The three-generation
structure in combination with the available genome-wide genetic data
enables unique opportunities for the analysis of environmental and ge-
netic traits. The family design of LifeLines enables inclusions of three
generation families and has advantages with respect to multiple-level
information, separation of non-genetic and genetic familial transmis-
sion. The prevalence of CVD risk factors and conditions is abundant in
LifeLines and enables researchers to improve our knowledge on CVD
and healthy cardiovascular ageing. A remarkable high percentage of un-
treated CVD risk factors in LifeLines suggest that not all opportunities to
reduce the CVD burden are utilised.
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